{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:37:59Z","timestamp":1789713479778,"version":"4.0.1"},"reference-count":154,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mesothelin (MSLN) is a cell surface glycoprotein with limited expression in normal tissues but frequent overexpression in solid tumors, including gynecological malignancies. This review summarizes the state of the art on the biological role, diagnostic value, prognostic significance, and therapeutic potential of MSLN in ovarian, endometrial, and cervical cancers. Evidence from clinical and experimental studies indicates that MSLN contributes to tumor progression through interactions with CA125, promotion of cell adhesion and peritoneal metastasis, activation of oncogenic signaling pathways, modulation of immune responses, and development of chemoresistance. Elevated MSLN expression has been associated with advanced clinical stage of the disease, platinum resistance, and poorer survival outcomes, particularly in ovarian cancer patients, although prognostic findings remain inconsistent. Circulating soluble MSLN may serve as a minimally invasive biomarker and may improve diagnostic accuracy when combined with established markers. Therapeutic MSLN strategies\u2014antibody-drug conjugates, CAR-T and NK cell therapies, monoclonal antibodies, immunotoxins, vaccines, and checkpoint blockade\u2014provide promising pre-clinical and early clinical results, particularly in resistant or recurrent forms of the disease. Overall, MSLN constitutes a promising target for precision oncology in gynecological cancers, although further clinical studies are required to validate its diagnostic utility and optimize targeted therapeutic approaches.<\/jats:p>","DOI":"10.3390\/cancers18111692","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:52Z","timestamp":1779452092000},"page":"1692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Mesothelin in Gynecological Tumors and Its Significance in Targeted Therapies\u2014A Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-5859","authenticated-orcid":false,"given":"Weronika","family":"Kawecka","sequence":"first","affiliation":[{"name":"Department of Surgical and Oncological Gynecology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek R.","family":"Wilczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Surgical and Oncological Gynecology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7754-9956","authenticated-orcid":false,"given":"Magdalena","family":"Tyczy\u0144ska","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-8069","authenticated-orcid":false,"given":"Micha\u0142","family":"Bielak","sequence":"additional","affiliation":[{"name":"Child Neurology Department, Children\u2019s Hospital University of Lublin, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-1860","authenticated-orcid":false,"given":"Bogdan","family":"Obrzut","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, University of Rzesz\u00f3w, 35-959 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-9437","authenticated-orcid":false,"given":"Andrzej","family":"Semczuk","sequence":"additional","affiliation":[{"name":"2nd Department of Gynecological Surgery and Gynecological Oncology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14740\/wjon1655","article-title":"Biology of mesothelin and clinical implications: A review of existing literature","volume":"5","author":"Hagerty","year":"2023","journal-title":"World J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A.M., Kluth, M., Hube-Magg, C., Blessin, N.C., and Fraune, C. (2021). Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040397"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/mcbr.2000.0181","article-title":"Structure of the Mesothelin\/MPF gene and characterization of its promoter","volume":"3","author":"Urwin","year":"2000","journal-title":"Mol. Cell Biol. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","article-title":"A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5","volume":"269","author":"Yamaguchi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","article-title":"Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas","volume":"34","author":"Frierson","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Takamizawa, S., Yazaki, S., Kojima, Y., Yoshida, H., Kitadai, R., Nishikawa, T., Shimoi, T., Sudo, K., Okuma, H.S., and Tanioka, M. (2022). High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: A retrospective study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10277-0"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/ijc.29185","article-title":"Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer","volume":"136","author":"Sasaki","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155562","DOI":"10.1016\/j.prp.2024.155562","article-title":"Mesothelin promotes the migration of endometrioid carcinoma and is associated with the MELF pattern","volume":"262","author":"Tahara","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.str.2024.04.011","article-title":"Structural elucidation of the mesothelin-mucin-16\/CA125 interaction","volume":"32","author":"Rupert","year":"2024","journal-title":"Structure"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7150\/ijbs.52097","article-title":"Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3\/FOXO3 pathway","volume":"17","author":"Huo","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"D752","DOI":"10.1093\/nar\/gky1099","article-title":"Update of the FANTOM web resource: Expansion to provide additional transcriptome atlases","volume":"47","author":"Lizio","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13059-014-0560-6","article-title":"Gateways to the FANTOM5 promoter level mammalian expression atlas","volume":"16","author":"Lizio","year":"2015","journal-title":"Genome Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-tissue expression (GTEx) project","volume":"45","author":"Lonsdale","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3802\/jgo.2024.35.e11","article-title":"Mesothelin expression in gynecologic carcinosarcoma: Clinicopathological significance and correlation with HER2 expression","volume":"35","author":"Kitadai","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, Y., Tian, W., Zhang, H., Zhang, Z., Zhao, Q., Chang, L., Lei, N., and Zhang, W. (2022). MSLN correlates with immune infiltration and chemoresistance as a prognostic biomarker in ovarian cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.830570"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12026-021-09211-6","article-title":"Recent advances in the role of Th17\/Treg cells in tumor immunity and tumor therapy","volume":"69","author":"Qianmei","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature24293","article-title":"IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity","volume":"551","author":"Molgora","year":"2017","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_33","first-page":"93","article-title":"Epidemiology and risk factors for ovarian cancer","volume":"22","author":"Ali","year":"2023","journal-title":"Prz. Menopauzalny"},{"key":"ref_34","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Biernacka, K., \u0141ukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., and Makowska, M. (2025). Ovarian cancer\u2014Epidemiology, classification, pathogenesis, treatment, and estrogen receptors\u2019 molecular backgrounds. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104611"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.3802\/jgo.2020.31.e70","article-title":"FIGO staging in ovarian carcinoma and histological subtypes","volume":"31","author":"Kehoe","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Barili, V., Ambrosini, E., Bortesi, B., Minari, R., De Sensi, E., Cannizzaro, I.R., Taiani, A., Michiara, M., Sikokis, A., and Boggiani, D. (2024). Genetic basis of breast and ovarian cancer: Approaches and lessons learnt from three decades of inherited predisposition testing. Genes, 15.","DOI":"10.3390\/genes15020219"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gambini, D., Ferrero, S., and Kuhn, E. (2022). Lynch Syndrome: From carcinogenesis to prevention interventions. Cancers, 14.","DOI":"10.3390\/cancers14174102"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1471-0528.2008.01772.x","article-title":"Identifying symptoms of ovarian cancer: A qualitative and quantitative study","volume":"115","author":"Bankhead","year":"2008","journal-title":"BJOG"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2016.682","article-title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer","volume":"5","author":"Wei","year":"2016","journal-title":"Biomed. Rep."},{"key":"ref_42","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhang, R., Siu, M.K.Y., Ngan, H.Y.S., and Chan, K.K.L. (2022). Molecular biomarkers for the early detection of ovarian cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231912041"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.09.028","article-title":"CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: From The Danish \u201cMALOVA\u201d Ovarian Cancer Study","volume":"104","author":"Christensen","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41416-021-01697-z","article-title":"Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer","volume":"126","author":"Mukama","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E465","DOI":"10.3399\/BJGP.2020.0859","article-title":"CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: A retrospective cohort study using electronic health records","volume":"71","author":"Funston","year":"2021","journal-title":"Br. J. Gen. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-018-1489-4","article-title":"Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer","volume":"16","author":"Gu","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gentry-Maharaj, A., Blyuss, O., Ryan, A., Burnell, M., Karpinskyj, C., Gunu, R., Kalsi, J.K., Dawnay, A., Marino, I.P., and Manchanda, R. (2020). Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. Cancers, 12.","DOI":"10.3390\/cancers12071931"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"James, N.E., Chichester, C., and Ribeiro, J.R. (2019). Beyond the biomarker: Understanding the diverse roles of human epididymis protein 4 in the pathogenesis of epithelial ovarian cancer. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00124"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejogrb.2018.10.008","article-title":"Diagnostic value of HE4 in ovarian cancer: A meta-analysis","volume":"231","author":"Huang","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.clinbiochem.2013.03.010","article-title":"Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients","volume":"46","author":"Leung","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jogoh.2018.03.010","article-title":"Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125","volume":"47","author":"Zheng","year":"2018","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.clinbiochem.2004.04.009","article-title":"Human kallikrein 11: An indicator of favorable prognosis in ovarian cancer patients","volume":"37","author":"Diamandis","year":"2004","journal-title":"Clin. Biochem."},{"key":"ref_58","first-page":"1918","article-title":"Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer","volume":"25","author":"Zhang","year":"2020","journal-title":"J. BUON"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Scholz, C., Heublein, S., Lenhard, M., Friese, K., Mayr, D., and Jeschke, U. (2012). Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res. Notes, 5.","DOI":"10.1186\/1756-0500-5-551"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: Implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study","volume":"111","author":"Madore","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1590\/0001-3765201620150107","article-title":"Mesothelin as a biomarker for ovarian carcinoma: A meta-analysis","volume":"88","author":"Madeira","year":"2016","journal-title":"An. Acad. Bras. Cienc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40291-017-0255-2","article-title":"Correlation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: A potential noninvasive biomarker for mesothelin-targeted therapy","volume":"21","author":"Hanaoka","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Schwarz, F.M., Klotz, D.M., Wimberger, P., and Kuhlmann, J.D. (2024). Urinary-based detection of MSL, HE4 and CA125 as an additional dimension for predictive and prognostic modelling in ovarian cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1392545"},{"key":"ref_65","first-page":"1549","article-title":"High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis","volume":"24","author":"Yildiz","year":"2019","journal-title":"J. BUON"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-020-01520-w","article-title":"Mesothelin expression in patients with high-grade serous ovarian cancer does not predict clinical outcome but correlates with CD11c+ expression in tumor","volume":"37","author":"Magalhaes","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tegeler, C.M., Scheid, J., Rammensee, H.G., Salih, H.R., Walz, J.S., Heitmann, J.S., and Nelde, A. (2022). HLA-DR presentation of the tumor antigen MSLN associates with clinical outcome of ovarian cancer patients. Cancers, 14.","DOI":"10.3390\/cancers14092260"},{"key":"ref_69","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2014.05.018","article-title":"Endometrial cancer: A review and current management strategies: Part I","volume":"134","author":"Burke","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"International Agency for Reseach on Cancer Handbook Working Group: Body Fatness and Cancer\u2014Viewpoint of the IARC Working Group","volume":"375","author":"Scoccianti","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: Have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41436-019-0536-8","article-title":"The proportion of endometrial cancers associated with Lynch syndrome: A systematic review of the literature and meta-analysis","volume":"21","author":"Ryan","year":"2019","journal-title":"Genet. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN Mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jamainternmed.2018.2820","article-title":"Association of endometrial cancer risk with postmenopausal bleeding in women. A systematic review and meta-analysis","volume":"178","author":"Clarke","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_78","first-page":"1510","article-title":"Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities","volume":"280","author":"Kerlikowske","year":"1998","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1469-0705.1996.07050322.x","article-title":"Transvaginal sonography of the endometrium in a representative sample of postmenopausal women","volume":"7","author":"Gull","year":"1996","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"850812","DOI":"10.1155\/2010\/850812","article-title":"Diagnostic strategies for postmenopausal bleeding","volume":"2010","author":"Breijer","year":"2010","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Committee on Gynecologic Practice (2018). ACOG Committee Opinion No. 734: The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet. Gynecol., 131, e124\u2013e129.","DOI":"10.1097\/AOG.0000000000002631"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/annonc\/mdx753","article-title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","volume":"29","author":"Wortman","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2013.02.023","article-title":"Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial","volume":"129","author":"Brinton","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/PAS.0000000000001220","article-title":"Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas","volume":"43","author":"Sari","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-17-0566","article-title":"Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma","volume":"23","author":"Depreeuw","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-018-08145-2","article-title":"A recurrent cancer-associated substitution in DNA polymerase \u03b5 produces a hyperactive enzyme","volume":"10","author":"Xing","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial carcinomas with POLE enonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/modpathol.2015.147","article-title":"Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer","volume":"29","author":"Stelloo","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): Updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/modpathol.2013.209","article-title":"Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma","volume":"27","author":"Kuhn","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_99","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","article-title":"Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2","volume":"27","author":"Walker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(10)70145-5","article-title":"Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): A randomised trial","volume":"11","author":"Janda","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_102","first-page":"CD006655","article-title":"Laparoscopy versus laparotomy for the management of early stage endometrial cancer","volume":"10","author":"Galaal","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/AOG.0b013e3181f74153","article-title":"Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches","volume":"116","author":"Gaia","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_104","first-page":"CD007585","article-title":"Lymphadenectomy for the management of endometrial cancer","volume":"10","author":"Frost","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.5608","article-title":"Endometrial carcinoma: Molecular subtypes, precursors and the role of pathology in early diagnosis","volume":"253","author":"Huvila","year":"2021","journal-title":"J. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13000-021-01093-4","article-title":"Significance of mesothelin and CA125 expression in endometrial carcinoma: A retrospective analysis","volume":"16","author":"Kakimoto","year":"2021","journal-title":"Diagn. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/ijgc-2024-005579","article-title":"Cervical cancer: A new era","volume":"34","author":"Caruso","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_109","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2021.10.075","article-title":"Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends","volume":"163","author":"He","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ijgc-2022-003703","article-title":"Updates on cervical cancer prevention","volume":"33","author":"Fernandes","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.3399\/bjgp14X681757","article-title":"Delays in diagnosis of young females with symptomatic cervical cancer in England: An interview-based study","volume":"64","author":"Lim","year":"2014","journal-title":"Br. J. Gen. Pract."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/fampra\/cmr033","article-title":"Gynaecological symptoms reported by young women: Examining the potential for earlier diagnosis of cervical cancer","volume":"28","author":"Stapley","year":"2011","journal-title":"Fam. Pract."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JGO.2016.003954","article-title":"Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline","volume":"2","author":"Chuang","year":"2016","journal-title":"J. Glob. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2022.08.013","article-title":"Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review","volume":"167","author":"Tan","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Kutle, I., Polten, R., Stalp, J.L., Hachenberg, J., Todzey, F., Hass, R., Zimmermann, K., von der Ohe, J., von Kaisenberg, C., and Neubert, L. (2024). Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1485461"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Hilliard, T.S. (2018). The impact of Mesothelin in the ovarian cancer tumor microenvironment. Cancers, 10.","DOI":"10.3390\/cancers10090277"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody\u2013drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s44178-024-00114-8","article-title":"Research progress of antibody\u2013drug conjugates in gynecologic cancer","volume":"3","author":"Xu","year":"2024","journal-title":"Hol. Integr. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00404-020-05734-9","article-title":"Favorable therapeutic response after anti-Mesothelin antibody\u2013drug conjugate treatment requires high expression of mesothelin in tumor cells","volume":"302","author":"Lazzerini","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An antimesothelin-monomethyl auristatin E conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"B057","DOI":"10.1158\/1535-7163.TARG-19-B057","article-title":"Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","volume":"18","author":"Clarke","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody\u2013drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/01480545.2021.2005085","article-title":"Preclinical safety profile of RC88-ADC a novel mesothelin-targeted antibody conjugated with monomethyl auristatin E","volume":"46","author":"Jiang","year":"2023","journal-title":"Drug Chem. Toxicol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Cutri-French, C., Nasioudis, D., George, E., and Tanyi, J.L. (2024). CAR-T Cell Therapy in ovarian cancer: Where are we now?. Diagnostics, 14.","DOI":"10.3390\/diagnostics14080819"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: A race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","article-title":"Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells","volume":"31","author":"Haas","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e001162","DOI":"10.1136\/jitc-2020-001162","article-title":"\u03b1PD-1-mesoCAR-T cells partially inhibit the growth of advanced\/refractory ovarian cancer in a patient along with daily apatinib","volume":"9","author":"Fang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114","DOI":"10.18632\/oncotarget.445","article-title":"Modulating mesothelin shedding to improve therapy","volume":"3","author":"Zhang","year":"2012","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy","volume":"20","author":"Alewine","year":"2015","journal-title":"Oncologist"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_147","first-page":"208ra147","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"23","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin\u2013CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A Live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-025-04032-0","article-title":"Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy","volume":"74","author":"Reischer","year":"2025","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:23:03Z","timestamp":1779452583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":154,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111692"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111692","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}